Introduction {#s1}
============

Porcine reproductive and respiratory syndrome (PRRS) causes substantial economic losses in pig production worldwide ([@B1]--[@B4]). In the United States, the estimated annual cost of PRRS on the national level was estimated at US \$664 million, based on a population size of 5.8 million breeding sows and 110 million pigs marketed per year ([@B2]). At farm level, costs due to PRRS depend on the individual farm situation including factors such as disease severity, affected production stages, or farm size. Median losses in a farrow-to-finish farm in Germany with 1,000 working sows moderately affected in all production stages were estimated at € 442′973 per year ([@B3]). Both the reproduction component of the disease manifested in breeding sows and the respiratory component in growing pigs contribute substantially to the economic losses ([@B2], [@B3]).

Various strategies have been developed to control PRRS. Apart from elimination procedures with the aim to create a completely virus-negative herd (e.g., closure and roll-over) or improvement of biosecurity and management, vaccination against PRRS is a common approach to control the disease ([@B5]). Depending on individual farm situation, several intervention strategies have shown to be profitable, with mass vaccination of sows or mass vaccination of sow and piglets being amongst the most cost efficient control strategies ([@B6]).

Besides the commercially available inactivated vaccines and modified-live virus vaccines (MLV), new techniques for administration have been explored and developed and research on the use of DNA vaccines to further improve efficacy of MLV vaccines has been conducted ([@B7]--[@B9]). However, current vaccines fail to provide complete protection against heterologous field strains and commercially available vaccines only partially prevent or mitigate the disease and show limited effectiveness in the field ([@B10]--[@B13]).

Most literature on vaccine efficacy describes effects under ideal study conditions. Typically, vaccine efficacy is assessed in experimentally infected pigs and refers to clinical, virological, or pathological findings after challenge under experimental conditions. Outcomes are reported as reduction of viremia in terms of duration and/or magnitude, of clinical signs or of pathological lesions ([@B11], [@B14]). Moreover, vaccine effectiveness might also be considered by epidemiological parameters describing disease dynamics and a reduction in virus transmission ([@B15], [@B16]).

Literature on vaccination effectiveness in the field and the impact on production parameters is scarce ([@B17]). However, this information is needed for farmers to convert positive effects of vaccination into monetary values and to estimate financial benefits through economic assessments and gross margin analyses ([@B18]). Moreover, the benefit of a vaccine in relation to its cost and thus vaccine price and return on investment are determining factors that influence farmer\'s attitude and willingness to pay for a vaccine ([@B19]). When trying to estimate financial benefits on a national level, these are important aspects, which might affect vaccination coverage and the proportion of farmers adopting a new vaccine. With these preconditions, scenario modeling and stochastic simulations are common approaches used to account for missing information and uncertainty.

The aim of this study was to assess economic effects associated with vaccination against PRRS and to estimate financial benefits on animal, herd, and national level. To evaluate the impact of various vaccine characteristics, different levels of vaccination effectiveness, vaccine price, and vaccination coverage were modeled.

Materials and Methods {#s2}
=====================

Model Description
-----------------

The economic assessment of vaccination against PRRS is based on a stochastic model developed by Nathues et al. ([@B3]). The initial model estimated the financial burden of disease in endemically PRRSV-infected farms and served as baseline to model the economic efficiency of different control strategies against PRRS ([@B6]). To estimate the potential financial benefit of different vaccine characteristics and vaccination scenarios within this project, the initial model was adapted and expanded accordingly. The model was built in Excel (Microsoft Corporation, Redmont, Washington, USA) and the Add-on \@Risk was used (Palisade Corporation, Newfield, New York, USA) to account for uncertainty and variability of parameters. The spreadsheet model consisted of several sub-models, which were linked with each other. Production parameters and epidemiological effects were identified and assessed in a literature review and implemented into the initial model. The production model simulated production dynamics within a timeframe of one year. The epidemiological flow model simulated disease impact according to defined disease status and incorporated these effects into the production model. In the intervention model, the cost and effectiveness associated with different vaccine characteristics and intervention strategies were defined and linked with the production and epidemiological model. The economic impact of disease and intervention was assessed by performing a gross margin analysis using production model outputs. The gross margin was defined as the total revenue minus variable cost. Variable cost consisted of replacement cost, market prices for sold or slaughtered animals, feeding cost, veterinary cost, cost for disposal of dead animals, variable energy cost, and miscellaneous cost. Full details of the baseline model, including prices of economic parameters, can be obtained from Nathues et al. ([@B3]) and the [Supplementary Material](#SM1){ref-type="supplementary-material"}. Stochastic simulations were run with 1,000 iterations per scenario. For the most part, stochastic model outputs were not normally distributed and estimates are, unless stated otherwise, reported as medians.

Farm Description
----------------

To model economic effects at farm-level, a typical farrow-to-finish farm from a pig-dense region in Germany was chosen to serve as an example farm. As this farm type contains all three production stages (breeding, nursing, and fattening), it was possible to capture financial effects for each of the three production parts separately. Furthermore, this approach permits that the model could also be used for economic evaluations of farms that only have one or two of the production parts (i.e., breeding herd with the sale of weaners, breeding herd with the sale of nursery pigs, nursery only, fattening only). The example farm has 1,000 working sows, batch-wise farrowing every week, 3 weeks suckling period, an annual replacement rate of 35%, and finishers are sold at 120 kg live weight. A detailed description of farm characteristics is listed in [Table 1](#T1){ref-type="table"}. For the disease impact estimation, it was assumed that field virus was newly detected in a farm endemically infected with PRRSV. The farm previously did not vaccinate against PRRS and both reproduction and respiratory components of the disease were present in the herd. Consequently, it was expected that clinical effects would occur in all production parts along with reduced performance and production output in breeding, nursing, and fattening. Values of production parameters of a PRRS negative farm, a PRRSV-infected farm, and absolute disease effects are listed in [Table 2](#T2){ref-type="table"}. Negative farm data was obtained from industry reports ([@B20], [@B21]) whereas information on the magnitude of disease effects in endemically PRRSV-infected farms was assessed through an expert poll conducted within the study framework of the initial model ([@B3]). Out of various scenarios with different levels of disease severity described in the initial model, a moderate scenario with median values for clinical affectedness was selected to serve as basis for the conducted analyses.

###### 

Farm characteristics of the example farrow-to-finish farm used for the economic model.

  **Parameter**                                     **Value**
  ------------------------------------------------- -----------
  Number of working sows                            1,000
  Production rhythm (weeks)                         3
  Duration of suckling period (weeks)               3
  Replacement rate (%)                              35
  Feed consumption during gestation (kg)            275
  Feed consumption during lactation (kg)            200
  Downtime between turns in nursery pens (days)     2
  Downtime between turns in fattening pens (days)   5
  Weight after nursery (kg)                         30
  Weight at slaughter (kg)                          120

###### 

Production parameters with assumed values of a PRRS negative farm and a PRRSV-infected farm with corresponding absolute disease effects.

  **Parameter**                                   **Negative farm**   **Infected farm**   **Disease effect**
  ----------------------------------------------- ------------------- ------------------- --------------------
  Return-to-oestrus rate                          10.0%               13.5%               +3.5%
  Abortion rate                                   2.0%                3.9%                +1.9%
  Average piglets born alive per sow and litter   12.7                11.4                −1.3
  Pre-weaning mortality                           11.0%               13.5%               +2.5%
  Weight at weaning                               6.0 kg              5.5 kg              −0.5 kg
  Days in nursery                                 45 days             50 days             +5 days
  PRRS morbidity in weaners                       --                  20.0%               +20.0%
  Mortality in weaners                            3.0%                10.0%               +7.0%
  Days in fattening                               119                 127 days            +8 days
  PRRS morbidity in fatteners                     --                  20.0%               +20.0%
  Mortality in fatteners                          1.5%                3.0%                +1.5%

Vaccination Strategies and Vaccine Characteristics
--------------------------------------------------

Two different vaccination strategies were considered in the model: (i) mass vaccination of sows only (MS) and (ii) mass vaccination of sows and vaccination of piglets (MSP). For MS, the vaccination protocol comprised a basic immunization of all sows and a booster vaccination 4 weeks later. After this, the entire sow herd is periodically vaccinated every 3 month. Incoming gilts are vaccinated twice during acclimatization. The MSP strategy is following the same protocol as the MS but with additional vaccination of piglets between the ages of 2--3 weeks.

The two main vaccine characteristics and associated economic effects examined in this study were vaccination effectiveness and vaccine price. For the economic modeling, the vaccination effectiveness was defined as the proportion by which disease effects in production parameters would be reduced after vaccination. Thus, related data on the improved of production output was required for implementation into the production model. The effectiveness of a vaccine when deployed in the field depends not only on the vaccine efficacy under ideal conditions but also on the characteristics of the population to whom it is administered and the comparison population ([@B14]). Since no evidence-based data was available, different levels of vaccination effectiveness were modeled: 50, 60, 70, 80, and 90%. In this context, an assumed vaccination effectiveness of 80% would mean the following: If the baseline abortion rate in a PRRS negative farm is 2% and in a PRRSV-infected farm 3.9%, the absolute disease effect is +1.9% ([Table 1](#T1){ref-type="table"}). Vaccination would reduce disease effects by 80% (−1.52%) and the abortion rate would persist at 2.38% after vaccination. To account for uncertainty and variation of vaccine price, several scenarios with different price levels were modeled: €0.75, 1.00, 1.25, and 1.50. The vaccine price was defined as the price per dose (including labor) for the single vaccination of one sow. For the MSP strategy, vaccination of a piglet would cost 80% of the price of sow vaccination.

National-Level Analyses and Vaccination Coverage
------------------------------------------------

The estimation of national-level benefits was based on outcomes from farm-level analyses. Demographic data on the pig population in Germany was obtained from the Federal Statistical Office ([@B22]). Overall, there are 27.2 million pigs, located on 23,800 farms. Of these, 8,400 farms hold breeding sows with totally 1.9 million sows. Herd-level prevalence show regional differences and is estimated to be between 50 and 100%, with high prevalence particularly in pig dense regions ([@B23]).

For the analyses, the breeding sow population was divided into two groups: previously vaccinated sows (preVS) and previously non-vaccinated sows (pnonVS). Previously vaccinated sows were defined as sows that were vaccinated against PRRS with a licensed and commercially available vaccine in the past. On the other hand, pnonVS were defined as sows that were not vaccinated against PRRS yet. The proportion of preVS is equivalent to the initial vaccination coverage whereas the proportion of pnonVS is equal to one minus the vaccination coverage. No empiric data on vaccination coverage was available and consequently different levels of preVS and pnonVS were modeled to account for uncertainty of this parameter. The proportion of sows that were vaccinated with a potential new vaccine (nVac) was independent from vaccination coverage and could be different in preVS and pnonVS. In preVS, it described the switch from a previously used licensed vaccine to nVac, whereas in pnonVS it described the switch from not vaccinating sows to newly vaccinating sows using nVac.

Different levels of vaccination effectiveness were modeled in the national-level analyses. For pnonVS, these comprised 50, 60, 70, 80, and 90%. For preVS, vaccination effectiveness of nVac was expressed as absolute change in effectiveness and five levels were considered (+5, +10, +15, +20, and +25%). For example, an effectiveness of +5% implied that disease effects were reduced by an additional 5%, compared to the previously used vaccine. To estimate financial benefits at national level, individual benefits per breeding sow were extrapolated. Animal-level benefits used as input values were obtained from farm-level analyses and were then multiplied by the corresponding number of affected animals. For national-level analyses, vaccine price was fixed at €1 for all scenarios.

Results {#s3}
=======

Financial losses due to PRRS, expressed as difference in gross margin between a PRRSV negative and a PRRSV-infected farrow-to-finish farm with disease effects according to [Table 2](#T2){ref-type="table"} and 1,000 working sows were €400,018 per year ([Figure 1](#F1){ref-type="fig"}). The median farm-level financial benefit attributable to vaccination with nVac ranged from €147,525 to 269,759 when sows only are vaccinated ([Table 3](#T3){ref-type="table"}) and from €169,563 to 339,643 in the MSP strategy, when piglets are also vaccinated ([Table 4](#T4){ref-type="table"}). Consequently, annual animal-level benefits per working sow attributable to vaccination were estimated to be between €148 and 270 for MS ([Figure 2](#F2){ref-type="fig"}) and between €170 and 340 for MSP ([Figure 3](#F3){ref-type="fig"}). These two figures give an overview of the associations between the modeled vaccine characteristics and financial benefits per working sow. The magnitude of financial benefits generated was more sensitive to a change in vaccination effectiveness than the variation of vaccine price. Particularly in the MS strategy, vaccine price had only minor effects on the profitability, whereas effects were more pronounced when piglets are vaccinated as well. For all modeled scenarios, the MSP strategy was more beneficial than MS when identical vaccine characteristics were assumed.

![Annual gross margins for a PRRS negative farm, a PRRSV-infected farm without vaccination ("diseased") and a PRRSV-infected farm with vaccination (MS and MSP strategy).](fvets-07-00500-g0001){#F1}

###### 

Differences in annual gross margin (in €) between a PRRSV-infected farm without intervention and a PRRS-infected farm with mass vaccination of sows (MS).

  **Vaccine price**   **Vaccination effectiveness**                                 
  ------------------- ------------------------------- --------- --------- --------- ---------
  €0.75               150′727                         179′865   209′149   239′455   269′759
  €1.00               149′581                         178′387   208′127   238′336   268′272
  €1.25               148′313                         177′482   207′020   237′136   267′480
  €1.50               147′525                         176′312   205′959   235′820   266′435

###### 

Differences in annual gross margin (in €) between a PRRSV-infected farm without intervention and a PRRSV-infected farm with mass vaccination of sows and piglets (MSP).

  **Vaccine price**   **Vaccination effectiveness**                                 
  ------------------- ------------------------------- --------- --------- --------- ---------
  €0.75               188′938                         225′481   262′646   300′798   339′643
  €1.00               182′137                         218′858   255′985   293′787   332′766
  €1.25               175′883                         211′992   249′089   287′053   325′839
  €1.50               169′563                         205′473   242′660   280′265   319′222

![Annual benefit per working sow, depending on vaccination effectiveness, and vaccine price, when vaccinating sows only (MS strategy) against PRRS.](fvets-07-00500-g0002){#F2}

![Annual benefit per working sow, depending on vaccination effectiveness, and vaccine price, when vaccinating sows and piglets (MSP strategy) against PRRS.](fvets-07-00500-g0003){#F3}

Financial benefits at national level were generated by adopting nVac to both preVS and pnonVS. Outputs were dependent on the variation of vaccination effectiveness, vaccination coverage, and the proportion of sows newly vaccinated with nVac.

In preVS, for each sow newly vaccinated with nVac, a median benefit of €3 was gained for every +1% of increased effectiveness compared with the effectiveness of the previously used vaccine. National-level financial benefits ranged from €2.3 to 45.7 million for the listed scenarios and a fixed vaccination effectiveness of +10% ([Table 5](#T5){ref-type="table"}). As an example, if 30% of sows were newly vaccinated with nVac and vaccination coverage was 60%, the annual financial benefit was estimated to be €10.3 million. If vaccination coverage was fixed at 60% and vaccination effectiveness varied from +5 to +25%, the financial benefit ranged from €1.7 to 85.8 million ([Table 6](#T6){ref-type="table"}). The proportion of sows newly vaccinated with nVac had a substantial effect on the magnitude of financial benefit, especially when effectiveness increased ([Figure 4](#F4){ref-type="fig"}).

###### 

Financial benefits (in €) associated with vaccination of previously vaccinated sows (preVS), when vaccination effectiveness of a potential new vaccine (nVac) is +10% compared to the previously used alternative vaccine.

  **Proportion of nVac in preVS**   **Vaccination coverage**                                          
  --------------------------------- -------------------------- ------------ ------------ ------------ ------------
  10%                               2′287′440                  2′859′300    3′431′160    4′003′020    4′574′880
  20%                               4′574′880                  5′718′600    6′862′320    8′006′040    9′149′760
  30%                               6′862′320                  8′577′900    10′293′480   12′009′060   13′724′640
  40%                               9′149′760                  11′437′200   13′724′640   16′012′080   18′299′520
  50%                               11′437′200                 14′296′500   17′155′800   20′015′100   22′874′400
  60%                               13′724′640                 17′155′800   20′586′960   24′018′120   27′449′280
  70%                               16′012′080                 20′015′100   24′018′120   28′021′140   32′024′160
  80%                               18′299′520                 22′874′400   27′449′280   32′024′160   36′599′040
  90%                               20′586′960                 25′733′700   30′880′440   36′027′180   41′173′920
  100%                              22′874′400                 28′593′000   34′311′600   40′030′200   45′748′800

*Estimates depend on vaccination coverage and the proportion of preVS that are newly vaccinated with nVac*.

###### 

Financial benefits (in €) due to vaccination of previously vaccinated sows (preVS) with nVac instead of a previously used licensed vaccine (vaccination coverage fixed at 60%).

  **Proportion of nVac in preVS**   **Vaccination effectiveness**                                          
  --------------------------------- ------------------------------- ------------ ------------ ------------ ------------
  10%                               1′715′580                       3′431′160    5′146′740    6′862′320    8′577′900
  20%                               3′431′160                       6′862′320    10′293′480   13′724′640   17′155′800
  30%                               5′146′740                       10′293′480   15′440′220   20′586′960   25′733′700
  40%                               6′862′320                       13′724′640   20′586′960   27′449′280   34′311′600
  50%                               8′577′900                       17′155′800   25′733′700   34′311′600   42′889′500
  60%                               10′293′480                      20′586′960   30′880′440   41′173′920   51′467′400
  70%                               12′009′060                      24′018′120   36′027′180   48′036′240   60′045′300
  80%                               13′724′640                      27′449′280   41′173′920   54′898′560   68′623′200
  90%                               15′440′220                      30′880′440   46′320′660   61′760′880   77′201′100
  100%                              17′155′800                      34′311′600   51′467′400   68′623′200   85′779′000

![Financial benefit associated with vaccination of previously vaccinated sows (preVS), when vaccination coverage is 60%, and vaccination effectiveness of nVac ranges from +5 to +25%.](fvets-07-00500-g0004){#F4}

In pnonVS, financial benefits per sow were substantially higher than in preVS. Median benefits per sow ranged from €150 to 268, depending on vaccination effectiveness and at a fixed vaccine price of €1. Already a small number of pnonVS newly vaccinated with nVac generated significant benefits at national level. If vaccination effectiveness varied between 50 and 90% and between 1 and 10% of sows were vaccinated with nVac, financial benefits ranged from €2.9 to 51.1 million ([Table 7](#T7){ref-type="table"}). If initial vaccination coverage was 50% and all of the pnonVS would newly be vaccinated with nVac, financial benefits would range from €143 to 256 million, depending on vaccination effectiveness ([Figure 5](#F5){ref-type="fig"}).

###### 

Financial benefits (in €) associated with vaccination of previously non-vaccinated sows (pnonVS) for different levels of vaccination effectiveness and proportion of newly vaccinated sows.

  **Proportion of sows vaccinated with nVac**   **Vaccination effectiveness**                                          
  --------------------------------------------- ------------------------------- ------------ ------------ ------------ ------------
  1%                                            2′851′317                       3′400′409    3′967′309    4′543′155    5′113′805
  2%                                            5′702′634                       6′800′818    7′934′618    9′086′310    10′227′609
  3%                                            8′553′951                       10′201′228   11′901′928   13′629′465   15′341′414
  4%                                            11′405′267                      13′601′637   15′869′237   18′172′620   20′455′219
  5%                                            14′256′584                      17′002′046   19′836′546   22′715′776   25′569′023
  6%                                            17′107′901                      20′402′455   23′803′855   27′258′931   30′682′828
  7%                                            19′959′218                      23′802′864   27′771′165   31′802′086   35′796′633
  8%                                            22′810′535                      27′203′273   31′738′474   36′345′241   40′910′437
  9%                                            25′661′852                      30′603′683   35′705′783   40′888′396   46′024′242
  10%                                           28′513′168                      34′004′092   39′673′092   45′431′551   51′138′047

![Financial benefit associated with vaccination of previously non-vaccinated sows (pnonVS) for different levels of vaccination effectiveness and proportions of newly vaccinated sows.](fvets-07-00500-g0005){#F5}

Discussion {#s4}
==========

Results from this study demonstrate that the introduction of nVac is associated with substantial financial benefits at animal, farm, and national level.

When interpreting farm-level outcomes it has to be considered that the estimated benefits are reported as differences in gross margin between a PRRSV-infected herd without previous intervention and a PRRSV-infected herd with intervention, in the form of vaccination. Furthermore, it was assumed that all production parts were affected by PRRS, which was associated with substantially reduced production performance and farm output and thus farm revenue. Therefore, it has to be taken into account that in practice it is likely that a farm showing such magnitudes of disease effects would already have implemented some sort of disease control, possibly in the form of vaccination with an already licensed and commercially available vaccine. This would imply that financial benefits of using nVac would have to be obtained from comparing farms vaccinating with nVac and farms vaccinating with an "old" vaccine. Consequently, reported estimates represent the maximum possible benefits based on the situation when no previous disease control was established. Financial benefits in farms that switch from an alternative vaccine to nVac are less pronounced, as demonstrated in the national-level models.

Estimates from this study are based on an example farm where both reproductive and respiratory traits were affected by PRRS. The reproduction parameters "abortion rate" and "number of piglets born alive" had a significant impact on gross margin. When an increased number of piglets are born due to improved reproductive performance after vaccination, more pigs go through the different production stages and eventually more fatteners are sold for slaughter. This had a direct impact on the farm output and consequently led to higher farm revenue. A main effect of the respiratory component of the disease is the reduced performance of growing pigs ([@B24], [@B25]). This effect is also reflected in the finding that the MSP strategy is more profitable than the MS. The additional cost for the piglet vaccination was compensated and surpassed by the improved production performance in the nursery and fattening stage.

The sensitivity analysis showed that the gross margin and associated economic profitability were more sensitive to vaccination effectiveness than to vaccine price. However, the range of vaccine prices included in the scenarios was limited. A potential novel vaccine stands in competition with other PRRS vaccines ([@B7]) and therefore its price would be influenced by the price of the already commercially available vaccines. Furthermore, it is likely that vaccination effectiveness and vaccine price are correlated. If vaccination effectiveness is high, farmers might be willing to pay more and when farmers can chose between different products, they would only purchase vaccines that are more expensive if vaccination effectiveness is increased accordingly ([@B26]). Overall, a "vaccine cost-benefit ratio," expressed as vaccine price compared to its vaccination effectiveness, could serve as key criteria in farmer\'s decision-making process. This implies that even if the vaccination effectiveness of nVac would be lower than the effectiveness of alternative vaccines, farmers might still switch to nVac under certain circumstances. Consequently, setting a market price for nVac without knowing its effectiveness in the field would be associated with a high level of uncertainty and thus different scenarios were modeled. In addition, market prices of vaccines do not only depend on its effectiveness alone, but do include many other criteria and are defined in a multi-step procedure ([@B27]) which implies that vaccine prices used in this model do not permit conclusions about production cost or margins of the vaccine manufacturer.

The results indicate that benefits generated in pnonVS are significantly higher than in preVS. This is because infected pnonVS showed substantially reduced production performance prior to vaccination whereas disease effects in preVS were already diminished due to vaccination with an alternative vaccine. However, the contribution to the overall financial benefit might still be larger from preVS than from pnonVS. It is likely that in practice, the proportion of sows newly vaccinated with nVac might be substantially higher in preVS than in pnonVS. It might be more challenging to convince farmers to start vaccinating their sows against PRRS (and chose nVac) than convincing farmers that already have been vaccinating their sows to switch to nVac. These farmers are already familiar with PRRS vaccination, associated cost, labor, and equipment and thus might be more likely to start using a new vaccine ([@B28]). A further point for discussion is the impact of nVac on the market equilibrium, associated with reduced disease prevalence ([@B29]). If a large proportion of farmers were vaccinating their sows, production performance would increase, more pigs would be marketed and eventually supply increases. This would lead to a shift of the supply curve and a change of market equilibrium associated with lower prices for farmers ([@B30]). However, market impacts were not considered in this study.

In the context of scenario analysis, reported financial benefits for different scenarios modeled in this study do not consider the plausibility of the corresponding scenario. The likelihood of a certain scenario has to be further investigated and supported with empiric data as no information on current vaccination coverage or public data on market shares of existing PRRS vaccines is available. Moreover, without yet knowing vaccination effectiveness and vaccine price, it is difficult to estimate to what extent nVac would be adopted in the field. The proportion of farmers that would switch from an alternative vaccine to nVac, as well as the proportion of farmers who would newly start vaccinating against PRRS, significantly depend on these key vaccine characteristics. Therefore, potential socio-economic benefits largely depend on farmers\' attitude toward PRRS vaccination and their decisions with respect to switching to a new vaccine ([@B31]). The behavior of a few single farmers might have a significant impact at national level, depending on their farm size. In Germany, farm sizes are rather heterogeneous ([@B22]). There are many small farms and only few large pig farms. When looking at breeding farms, 24% of them have \<50 sows but account for only 2% of the population. On the other hand, only 8% of farms have more than 500 sows but make up for 42% of all breeding sows in Germany. This implies that if a few owners of large farms decide to switch to nVac, a considerable number of sows are affected. However, the decision to switch to nVac might not only be a farmers\' own choice. The decision-making process might also be influenced and controlled by a number of external factors ([@B28]).

Conclusions {#s5}
===========

The analysis performed showed that while vaccination against PRRS was beneficial for all modeled scenarios, vaccinating both sows and piglets proved to be more profitable than vaccinating sows alone. The magnitude of benefits derived from vaccination was more sensitive to changes in vaccine effectiveness than to vaccine price changes. Actual economic benefits of nVac largely depend on the extent to which it would be adopted in the field and consequently also on farmer\'s attitude toward a new vaccine and willingness to pay.
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